Maine insurers must cover provider-recommended, medically necessary blood tests for PFAS chemicals for plan documents signed, issued, delivered, continued, or renewed on or after January 1, 2027.
Maine health plans must cover provider-recommended, medically necessary blood tests for PFAS chemicals. Coverage applies to plan documents signed, issued, delivered, continued, or renewed on or after January 1, 2027.
The law sets aside $90,000 from the General Fund for 2026–27 to cover costs of the PFAS testing requirement, with ongoing funding beginning January 1, 2027.
The law was enacted without the Bureau of Insurance’s usual review and evaluation of requirements for insurers to cover particular health benefits.
Insurers must cover blood tests for PFAS, a group of chemicals, when a health care provider recommends them as medically necessary. The requirement covers people enrolled in health plans offered in Maine. Testing is presumed medically necessary when a provider finds that the patient meets testing guidelines from the National Academies of Sciences, Engineering, and Medicine, its successor, or a comparable organization. Coverage applies to policies, contracts, and certificates executed, delivered, issued for delivery, continued, or renewed on or after January 1, 2027. Contracts count as renewed no later than their next yearly anniversary.
The law sets aside $90,000 from the General Fund for the State Benefit Mandate Defrayal program, which pays costs of required insurance benefits. The Department of Administrative and Financial Services receives the money to cover costs of the PFAS blood-test coverage requirement. Funding begins January 1, 2027. The spending table lists $0 for 2025–26 and $90,000 for 2026–27.
The law exempts this coverage requirement from the usual review and evaluation of required insurance benefits. The exemption concerns review by the Bureau of Insurance within the Department of Professional and Financial Regulation.
No hearings or votes scheduled.